National Cancer Institute; Notice of Closed Meeting, 47816 [06-7016]

Download as PDF 47816 Federal Register / Vol. 71, No. 160 / Friday, August 18, 2006 / Notices 1987’’ has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: Liz Berbakos, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482. SUPPLEMENTARY INFORMATION: In the Federal Register of June 2, 2006 (71 FR 32097), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0435. The approval expires on August 31, 2009. A copy of the supporting statement for this information collection is available on the Internet at https://www.fda.gov/ ohrms/dockets. Place: National Institutes of Health, 6130 Executive Blvd., EPN/6053, Rockville, MD 20852, (Telephone Conference Call). Contact Person: C. Michael Kerwin, PhD, MPH, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8057, Bethesda, MD 20892– 8329, (301) 496–7421, kerwinm@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 10, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6–13609 Filed 8–17–06; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: August 14, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–7016 Filed 8–17–06; 8:45 am] BILLING CODE 4140–01–M National Institutes of Health BILLING CODE 4160–01–S National Cancer Institute; Notice of Closed Meetings DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institutes of Health National Cancer Institute; Notice of Closed Meeting jlentini on PROD1PC65 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel—SBIR topic 207 (Phase II), ‘‘Multi-Purpose Radiophamaceutical Synthesis Platforms’’. Date: September 5, 2006. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate contract proposals. VerDate Aug<31>2005 18:35 Aug 17, 2006 Jkt 208001 Name of Committee: National Cancer Institute Special Emphasis Panel, Cancer Education and Cancer Development. Date: September 25, 2006. Time: 5:30 p.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Jeannette F Korczak, PhD, Scientific Review Administrator, Review Training Resources Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8115, Bethesda, MD 20892, 301–496–9767, korczak@mail.nih.gov. PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 Name of Committee: National Cancer Institute Initial Review Group, Subcommittee I—Career Development. Date: September 26–27, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007. Contact Person: Robert Bird, PhD, Scientific Review Administrator, Resources and Training Review Branch, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8113, MSC 8328, Bethesda, MD 20892–8328, 301– 496–7978, birdr@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Prevention, Control and Population Sciences. Date: September 27–29, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Hasnaa Shafik, MD, PhD, Scientific Review Administrator, Division of Extramural Activities, RPRB, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8037, Bethesda, MD 20892, (301) 451–4757, shafikh@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Innovations in Cancer Sample Preparation, STTR, SBIR. Date: October 4, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel and Conf. Center, 5701 Marinelli Road, Bethesda North, MD 20852. Contact Person: Gerald G. Lovinger, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8101, Bethesda, MD 20892–8329, 301/496–7987. lovingeg@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Clinical Program Project Special Emphasis Panel. Date: October 4–6, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton, 8727 Colesville Road, Silver Spring, MD 20910. Contact Person: Carol Lyman, PhD, Scientific Review Administrator, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd, Room 8119, Bethesda, MD 20892–8328, 301–451–4761, lymanc@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Discovery and Development. Date: October 4–6, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910. E:\FR\FM\18AUN1.SGM 18AUN1

Agencies

[Federal Register Volume 71, Number 160 (Friday, August 18, 2006)]
[Notices]
[Page 47816]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-7016]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4), and 552b(c)(6), as 
amended. The contract proposals and the discussions could disclose 
confidential trade secrets or commercial property such as patentable 
material, and personal information concerning individuals associated 
with the contract applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel--SBIR topic 207 (Phase II), ``Multi-Purpose Radiophamaceutical 
Synthesis Platforms''.
    Date: September 5, 2006.
    Time: 1 p.m. to 3 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6130 Executive Blvd., EPN/
6053, Rockville, MD 20852, (Telephone Conference Call).
    Contact Person: C. Michael Kerwin, PhD, MPH, Scientific Review 
Administrator, Special Review and Logistics Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 6116 
Executive Boulevard, Room 8057, Bethesda, MD 20892-8329, (301) 496-
7421, kerwinm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 14, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-7016 Filed 8-17-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.